Does Ado Trastuzumab Emtansine Interact with Nefazodone?
CDI records a major classification for Ado Trastuzumab Emtansine and Nefazodone. The stored summary is: Strong CYP3A4 inhibitor that may increase DM1 exposure and toxicity. Concomitant use should be avoided or KADCYLA treatment delayed. The mechanism involves inhibition of cyp3a4-mediated metabolism of dm1. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
Inhibition of CYP3A4-mediated metabolism of DM1
What To Tell Your Doctor or Pharmacist
If you are taking Ado Trastuzumab Emtansine and your doctor is considering prescribing Nefazodone (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider